Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal
US Government Will Fund Up To $268.8m In Production Site Upgrades
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
You may also be interested in...
The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.